SCHEMBL30765867

SCHEMBL30765867

C[C@H](Nc1cncn(CC(=O)O)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.44
NPC1 O15118 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 2/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 3/20 0.36
MMP12 P39900 2/20 0.36
MMP13 P45452 2/20 0.36
USP2 O75604 1/20 0.36
NPY5R Q15761 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
SOS1 Q07889 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765797 0.88 KMT2A (0.40) HDAC6NPC1HTTRAB9ASMN1; SMN2
SCHEMBL30765801 0.85 LMNA (0.41) NPC1RAB9AKMT2APOLBLMNA
SCHEMBL30765619 0.82 LMNA (0.38) HDAC6NPC1HTTRAB9ASMN1; SMN2
SCHEMBL31558435 0.81 ELANE (0.45) HDAC6LMNA
SCHEMBL30765814 0.81 LMNA (0.39) HDAC6HTTSMN1; SMN2KMT2APOLB
SCHEMBL31558430 0.80 HDAC6 (0.47) HDAC6NPC1HTTRAB9ASMN1; SMN2
SCHEMBL30765770 0.79 LMNA (0.38) HDAC6NPC1HTTRAB9ASMN1; SMN2
SCHEMBL31558409 0.79 POLB (0.36) HDAC6HTTPOLBLMNAMAPT
SCHEMBL30765710 0.79 LMNA (0.38) HDAC6NPC1HTTRAB9ASMN1; SMN2
SCHEMBL30765863 0.79 GAA (0.38) HDAC6HTTSMN1; SMN2KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed